Cite
Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.
MLA
Hilser, Thomas, et al. “Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.” Cancers, vol. 16, no. 17, Sept. 2024, p. 2998. EBSCOhost, https://doi.org/10.3390/cancers16172998.
APA
Hilser, T., Darr, C., Niegisch, G., Schnabel, M. J., Foller, S., Häuser, L., Zschäbitz, S., Lewerich, J., Ivanyi, P., Schlack, K., Paffenholz, P., Daetwyler, E., Niedersüß-Beke, D., & Grünwald, V. (2024). Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project. Cancers, 16(17), 2998. https://doi.org/10.3390/cancers16172998
Chicago
Hilser, Thomas, Christopher Darr, Günter Niegisch, Marco Julius Schnabel, Susan Foller, Lorine Häuser, Stefanie Zschäbitz, et al. 2024. “Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.” Cancers 16 (17): 2998. doi:10.3390/cancers16172998.